|
41 Companies |
|
29 Products |
|
29 Products |
|
22 Mechanisms of Action |
|
2 Trials |
|
854 News |
|
| «12...567891011121314151617» |
- | New P1/2 trial: Topical 3% Amphotericin B Cream for the Treatment of Cutaneous Leishmaniasis in Colombia (clinicaltrials.gov) - May 1, 2013
P1/2, N=80, Recruiting, Sponsor: Drugs for Neglected Diseases
- Clinical: Rapid Diagnostic Tests for Assessment of Initial Clearance and Detection of Recurrent Malaria Infections (clinicaltrials.gov) - Apr 29, 2013
P=N/A, N=53, Completed, Sponsor: Anders Björkman
- New P1 trial: A Phase I Clinical Trial Immunizing Healthy Adults With the NMRC-M3V-Ad-PfCA Vaccine to Generate Biologic Reagents (clinicaltrials.gov) - Apr 28, 2013
P1, N=35, Not yet recruiting, Sponsor: U.S. Army Medical Research and Materiel Command
- || Eurartesim (dihydroartemisinin/piperaquine) / Medicines for Malaria Venture, Leadiant Biosci
New P3 trial: PRINOGAM: Primaquine's Gametocytocidal Efficacy in Malaria Asymptomatic Carriers (clinicaltrials.gov) - Apr 22, 2013
P3, N=1200, Recruiting, Sponsor: Medical Research Council Unit, The Gambia
- Enrollment open: OZ439 PhIIa Study in Plasmodium Falciparum: Extended Observation (clinicaltrials.gov) - Apr 18, 2013
P2, N=32, Recruiting, Sponsor: Medicines for Malaria Venture
Not yet recruiting --> Recruiting
- Coarsucam (artesunate/amodiaquine) / Sanofi, DNDi
Enrollment closed: Amodiaquine-Artesunate & Artemether-Lumefantrine Efficacy in Burkina Faso (clinicaltrials.gov) - Apr 18, 2013
P4, N=150, Active, not recruiting, Sponsor: Centre Muraz
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Trial completion: A Dose-escalation Study to Investigate Safety and Toleration of OZ439 (clinicaltrials.gov) - Apr 18, 2013
P1, N=34, Completed, Sponsor: Medicines for Malaria Venture
Recruiting --> Active, not recruiting Recruiting --> Completed
- | cipargamin (KAE609) / Novartis
New P2 trial: A Study to Find the Minimum Inhibitory Concentration of KAE609 in Adult Male Patients With P. Falciparum Monoinfection (clinicaltrials.gov) - Apr 17, 2013
P2, N=48, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- artemether/lumefantrine / Generic mfg.
Trial completion, Combination therapy: Trial of Artemether-Lumefantrine Alone and in Combination With Ivermectin to Reduce Post-Treatment Malaria Transmission (clinicaltrials.gov) - Apr 16, 2013
P1/2, N=120, Completed, Sponsor: London School of Hygiene and Tropical Medicine
Recruiting --> Completed Recruiting --> Completed
- | New P4 trial: Trichomonas Vaginalis Repeat Infections Among HIV Negative Women (clinicaltrials.gov) - Apr 14, 2013
P4, N=2883, Recruiting, Sponsor: Tulane University Health Sciences Center
- Clinical: Malaria Transmission Studies in Mali (clinicaltrials.gov) - Apr 9, 2013
P=N/A, N=650, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- vivax malaria vaccine (ChAd63 PvDBP/MVA PvDBP) / University of Oxford
New P1 trial: Phase Ia Study of ChAd63/MVA PvDBP (clinicaltrials.gov) - Mar 19, 2013
P1, N=24, Active, not recruiting, Sponsor: University of Oxford
- chloroquine phosphate / Generic mfg.
New P4 trial: Pharmacokinetic Study of Multi-dose Chloroquine (clinicaltrials.gov) - Mar 18, 2013
P4, N=30, Completed, Sponsor: Bandim Health Project
- PEV 301 and PEV 302 in virosomes / Pevion
Trial completion: PMAL03: Phase Ib Trial of Two Virosome Formulated Malaria Vaccine Components (PEV 301, PEV 302) in Tanzania (clinicaltrials.gov) - Mar 13, 2013
P1, N=50, Completed, Sponsor: Swiss Tropical & Public Health Institute
Recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Optimisation of Controlled Human Malaria Infection Using Sporozoites Administered by Needle and Syringe (clinicaltrials.gov) - Mar 12, 2013
P=N/A, N=18, Completed, Sponsor: University of Oxford
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: AdCh63 ME-TRAP and MVA ME-TRAP Malaria Vaccines Evaluation in Healthy Adults and Children in a Malaria Endemic Area (clinicaltrials.gov) - Mar 12, 2013
P1, N=52, Completed, Sponsor: University of Oxford
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Promune (agatolimod) / Pfizer
Trial completion: Safety and Immunogenicity of Malaria Vaccines AdCh63 AMA1, MVA AMA1 and AMA1-C1/Alhydrogel (clinicaltrials.gov) - Mar 12, 2013
P1, N=35, Completed, Sponsor: University of Oxford
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Fluarix (influenza virus trivalent vaccine) / GSK
New P2/3 trial: Safety and Immunogenicity Study of Influenza Vaccines in HIV-infected and HIV-uninfected Pregnant Women in Western Kenya (clinicaltrials.gov) - Mar 11, 2013
P2/3, N=0, Withdrawn, Sponsor: Centers for Disease Control and Prevention
- | efavirenz / Generic mfg., nevirapine / Generic mfg., lopinavir/ritonavir / Generic mfg.
Enrollment change: PROMOTE-PEDS: HIV Protease Inhibitors for the Prevention of Malaria in Ugandan Children (clinicaltrials.gov) - Mar 10, 2013
P3, N=186, Completed, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed N=300 --> 186
- | efavirenz / Generic mfg., nevirapine / Generic mfg., lopinavir/ritonavir / Generic mfg.
Trial completion: PROMOTE-PEDS: HIV Protease Inhibitors for the Prevention of Malaria in Ugandan Children (clinicaltrials.gov) - Mar 10, 2013
P3, N=186, Completed, Sponsor: University of California, San Francisco
N=300 --> 186 Recruiting --> Completed
- | trimethoprim/sulfamethoxazole / Generic mfg., artemether/lumefantrine / Generic mfg.
Trial completion: TCC: Interactions Between HIV and Malaria in African Children (clinicaltrials.gov) - Mar 10, 2013
P3, N=351, Completed, Sponsor: University of California, San Francisco
Recruiting --> Completed Active, not recruiting --> Completed
- artemether/lumefantrine / Generic mfg.
Trial completion: Non-malarial Febrile Illness in Children in Areas of Perennial Malaria Transmission (clinicaltrials.gov) - Mar 7, 2013
P=N/A, N=1000, Completed, Sponsor: Centers for Disease Control and Prevention
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | trimethoprim/sulfamethoxazole / Generic mfg.
Trial completion: Establishing Effectiveness of Daily Co-trimoxazole Prophylaxis For Prevention of Malaria in Pregnancy (clinicaltrials.gov) - Mar 6, 2013
P3, N=848, Completed, Sponsor: Institute of Tropical Medicine, Belgium
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial withdrawal: Phase 1 Study of the Safety and Immunogenicity of a Malaria Transmission-blocking Pfs25-Pfs25 Conjugate Vaccine (clinicaltrials.gov) - Mar 5, 2013
P1, N=0, Withdrawn, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Active, not recruiting --> Completed Not yet recruiting --> Withdrawn
- Enrollment change: Phase 1 Study of the Safety and Immunogenicity of a Malaria Transmission-blocking Pfs25-Pfs25 Conjugate Vaccine (clinicaltrials.gov) - Mar 5, 2013
P1, N=0, Withdrawn, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Not yet recruiting --> Withdrawn N=60 --> 0
- Coarsucam (artesunate/amodiaquine) / Sanofi, DNDi
Trial completion: Efficacy of Artemether-lumefantrine, Artesunate-amodiaquine and Dihydroartemisinin-piperaquine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Malawi (clinicaltrials.gov) - Feb 20, 2013
P=N/A, N=498, Completed, Sponsor: Centers for Disease Control and Prevention
N=60 --> 0 Recruiting --> Completed
- mefloquine / Generic mfg.
Trial termination: Safety, Tolerability & Pharmacokinetics (PK) of Co-administered Single Doses of OZ439 and Mefloquine (MQ) in Healthy Volunteers (clinicaltrials.gov) - Feb 19, 2013
P1, N=24, Terminated, Sponsor: Medicines for Malaria Venture
Recruiting --> Completed Recruiting --> Terminated; Decision taken to halt progression of mefloquine as a potential partner for OZ439 as a single dose cure due to low probability of success
- mefloquine / Generic mfg.
Enrollment change: Safety, Tolerability & Pharmacokinetics (PK) of Co-administered Single Doses of OZ439 and Mefloquine (MQ) in Healthy Volunteers (clinicaltrials.gov) - Feb 19, 2013
P1, N=24, Terminated, Sponsor: Medicines for Malaria Venture
Recruiting --> Terminated; Decision taken to halt progression of mefloquine as a potential partner for OZ439 as a single dose cure due to low probability of success N=48 --> 24
- || gentamicin sulfate / Generic mfg.
New P3 trial: Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama (clinicaltrials.gov) - Feb 11, 2013
P3, N=300, Recruiting, Sponsor: U.S. Army Medical Research and Materiel Command
- Enrollment open: CL Detect (clinicaltrials.gov) - Feb 11, 2013
P=N/A, N=167, Recruiting, Sponsor: U.S. Army Medical Research and Materiel Command
N=48 --> 24 Not yet recruiting --> Recruiting
- || Enrollment change: Abbott ESA Chagas Assay Post-Market Study (clinicaltrials.gov) - Feb 4, 2013
P=N/A, N=63, Completed, Sponsor: Abbott Diagnostics Division
Not yet recruiting --> Recruiting N=50 --> 63
- ||| Trial completion: Abbott ESA Chagas Assay Post-Market Study (clinicaltrials.gov) - Feb 4, 2013
P=N/A, N=63, Completed, Sponsor: Abbott Diagnostics Division
N=50 --> 63 Enrolling by invitation --> Completed
- chloroquine phosphate / Generic mfg., azithromycin / Generic mfg.
New P1/2 trial: Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine or Chloroquine/Azithromycin Prophylaxis (clinicaltrials.gov) - Jan 31, 2013
P1/2, N=25, Not yet recruiting, Sponsor: Radboud University
- || New P3 trial: Evaluation of Vitamin A and Zinc Supplementation on Malarial Morbidity (clinicaltrials.gov) - Jan 30, 2013
P3, N=200, Completed, Sponsor: Kintampo Health Research Centre, Ghana
- primaquine / Generic mfg.
New P1 trial: Primaquine Pharmacokinetics in Lactating Women and Their Infants (clinicaltrials.gov) - Jan 29, 2013
P1, N=24, Recruiting, Sponsor: University of Oxford
- Trial completion: A Comparison of the Bioavailability of OZ439 When Delivered Directly to the Small Intestine, or Via the Oral Route (clinicaltrials.gov) - Jan 24, 2013
P1, N=11, Completed, Sponsor: Medicines for Malaria Venture
Enrolling by invitation --> Completed Recruiting --> Completed
- sulfadoxine/pyrimethamine / Generic mfg.
Trial completion: Reducing the Effects of Malaria in Children by Administering Repeated Preventive Doses (clinicaltrials.gov) - Jan 22, 2013
P4, N=1189, Completed, Sponsor: Albert Schweitzer Hospital
Recruiting --> Completed Active, not recruiting --> Completed
- Enrollment open: Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases In Patients With Persistent Fever in Cambodia, Nepal, Democratic Republic of the Congo and Sudan (NIDIAG-Fever) (clinicaltrials.gov) - Jan 21, 2013
P=N/A, N=2170, Recruiting, Sponsor: University Hospital, Geneva
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | trimethoprim/sulfamethoxazole / Generic mfg., mefloquine / Generic mfg.
Trial completion: PACOME: Prevention of Pregnancy-associated Malaria in HIV-infected Women: Cotrimoxazole Prophylaxis Versus Mefloquine (clinicaltrials.gov) - Jan 20, 2013
P3, N=430, Completed, Sponsor: Institut de Recherche pour le Developpement
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | New P1 trial: Optimization of Controlled Human Malarial Infection by Injection of P. Falciparum Sporozoites in Non-Immune Adults (clinicaltrials.gov) - Jan 16, 2013
P1, N=36, Completed, Sponsor: Sanaria Inc.
- atovaquone/proguanil / Generic mfg.
Trial completion: TIP4: Re-exposure of Human Volunteers to a Heterologous Strain of P. Falciparum Sporozoites (clinicaltrials.gov) - Jan 16, 2013
P=N/A, N=21, Completed, Sponsor: Radboud University
Active, not recruiting --> Completed Recruiting --> Completed
- artemether/lumefantrine / Generic mfg.
Trial completion: Artemether/Lumefantrine and Vivax Malaria (clinicaltrials.gov) - Jan 15, 2013
P3, N=38, Completed, Sponsor: University of Khartoum
Recruiting --> Completed Recruiting --> Completed
- | Trial completion: Neo-Penotran Forte Vaginal Suppository for Vaginal Trichomoniasis (clinicaltrials.gov) - Jan 14, 2013
P2, N=40, Completed, Sponsor: University of Alabama at Birmingham
Recruiting --> Completed Recruiting --> Completed
- nevirapine / Generic mfg., artemether/lumefantrine / Generic mfg.
Trial completion: Interactions Between Artemether-lumefantrine and Antiretrovirals in HIV-patients With Uncomplicated Malaria in Tanzania (clinicaltrials.gov) - Jan 14, 2013
P4, N=830, Completed, Sponsor: University of Copenhagen
Recruiting --> Completed Recruiting --> Completed
- amphotericin b liposome / Generic mfg.
Enrollment change: LVBrasil: Efficacy and Safety Study of Drugs for Treatment of Visceral Leishmaniasis in Brazil (clinicaltrials.gov) - Jan 13, 2013
P4, N=423, Recruiting, Sponsor: University of Brasilia
Recruiting --> Completed N=660 --> 423
- Biomarker: BIOMARCHA: New Tools for the Diagnosis, Prognosis and Treatment Follow-up in Chagas Disease (clinicaltrials.gov) - Dec 20, 2012
P=N/A, N=63, Recruiting, Sponsor: Barcelona Centre for International Health Research
- | Coarsucam (artesunate/amodiaquine) / Sanofi, DNDi, Eurartesim (dihydroartemisinin/piperaquine) / Medicines for Malaria Venture, Leadiant Biosci
New P4 trial, Combination therapy: Efficacy of Three ACTs for the Treatment of Falciparum Malaria in Maradi Niger (clinicaltrials.gov) - Dec 20, 2012
P4, N=663, Recruiting, Sponsor: Epicentre
- New P4 trial: CINEBENZ: Population Pharmacokinetics in Benznidazole-treated Adults With Chronic With Chagas Disease (clinicaltrials.gov) - Dec 20, 2012
P4, N=50, Active, not recruiting, Sponsor: Barcelona Centre for International Health Research
- Coarsucam (artesunate/amodiaquine) / Sanofi, DNDi
Enrollment change, Combination therapy: RDT-ACT: Restricting the Use of Artesunate Plus Amodiaquine Combination Therapy to Malaria Cases Confirmed by a Dipstick Test: A Cluster Randomised Control Trial (clinicaltrials.gov) - Dec 19, 2012
P4, N=3063, Completed, Sponsor: Kintampo Health Research Centre, Ghana
N=660 --> 423 N=2000 --> 3063
- Enrollment open: A Phase 1/2b Study of an Investigational Malaria Vaccination Strategy in 5-17 Month Old Infants and Children in Burkina Faso (clinicaltrials.gov) - Dec 19, 2012
P1/2, N=700, Recruiting, Sponsor: University of Oxford
N=2000 --> 3063 Not yet recruiting --> Recruiting